Aileron Therapeutics is creating one of the first new classes of drugs in 20 years. Our proprietary Stapled Peptide drugs uniquely capitalize on 25 years of genetic research to attack the key drivers of complex diseases such as cancer, metabolic and endocrine conditions and inflammation. By harnessing one of the most common, but elusive, structures in nature - the alpha helical peptide, we believe that we can dramatically improve the treatment of these diseases and positively impact the lives of millions of patients.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/14/13 | $42,000,000 | Series D |
Apple Tree Partners Excel Venture Management Novartis Venture Funds Roche Venture Fund SR One | undisclosed |
| 11/18/13 | $30,000,000 | Series E |
Apple Tree Partners Excel Venture Management Novartis Venture Funds Roche Venture Fund SR One | undisclosed |
| 10/29/14 | $33,000,000 | Series E |
AJU IB Investment Apple Tree Partners Excel Venture Management Novartis Venture Funds Roche Venture Fund SR One | undisclosed |
